Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Cost, LYs and QALYs per person for each screening strategy, and the incremental cost, LYs and QALYs of a screening strategy compared with no screening

From: Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing

Strategya No Screening Biennial G-FOBT Annual G-FOBT Colonoscopy every 10 years Biennial I-FOBT Annual I-FOBT
Cost ($USD) per person 2541 4221 5394 4752 4542 5068
Incremental cost (∆C, $) compared with no screening - 1681 2853 2212 2001 2528
Expected LYs per person 15.6420 15.6862 15.7104 15.7385 15.7429 15.7650
Incremental LYs compared with no screening - 0.0443 0.0684 0.0965 0.1009 0.1231
Expected QALYs per person 14.7479 15.0687 15.2339 15.3586 15.4203 15.5491
Incremental QALYs compared with no screening - 0.3207 0.4860 0.6106 0.6724 0.8012
  1. Note: G-FOBT, Guaiac fecal occult blood testing; I-FOBT, immunologic fecal occult blood testing
  2. aSort by ascending order of effectiveness
Back to article page